Adacyte events

When can GMA be useful in UC treatment? (in Spanish)

At present, a significant unmet therapeutic need exists for patients with ulcerative colitis (UC), despite the recent approval of several biologics and small molecules with diverse modes of action. Adacolumn could be a helpful alternative to manage UC in specific patient populations

June 17, 2021



The general goals for managing IBD are to eliminate symptoms of disease, improve quality of life, avoid hospitalization and surgery.
Nevertheless, current approved treatments don’t achieve these goals for every patient or they don’t control the disease all the time.

Indeed, the percentage of patients in clinical remission after one year of treatment, is less than 50% for most currently available therapies, whilst more demanding outcomes, such as endoscopic or histological healing, are accomplished by even less patients. In addition, biologics and small molecules are associated with certain safety concerns that may compromise their applicability to specific subpopulations with UC.

Taken together, novel therapeutic approaches that will demonstrate adequate efficacy combined with acceptable safety profiles are continually needed.

This high-level medical e-learning webinar with leading experts in IBD management will discuss if it is possible a promise of better and safer long-term outcomes with Adacolumn considering its differential mechanism of action vs. other alternatives. It covers also current clinical experience in Europe and practical aspect for its use in UC.

Dr. Eugeni Domènech
Head of the Gastroenterology & Hepatology Department and the Inflammatory Bowel Diseases Unit at the Hospital Universitari Germans Trias i Pujol. Coordinator for Gastrointestinal diseases of the IBDomics Consortium for genomic & translational research in immune-mediated inflammatory diseases, translational research and part of the CIBER-EHD Consortium (Spanish Ministry of Science). Member of various medical societies, among which the European Crohn’s and Colitis Organization (ECCO)

Dr. Alejandro Hernández
Department of Gastroenterology Hepatology Hospital l Universitario Ntra. Sra. de la Candelaria, Santa cruz de Tenerife, Canarias. Fellow in the Endoscopy Unit of the National Cancer Center of Tokio.

Gastroenterologists, Paediatric gastroenterologists and physicians and allied health professionals interested in therapeutic apheresis, including both established practitioners and those embarking on a new apheresis service (nephrologists, haematologists, clinical pathologists, blood bankers, nurses…etc).

Contact UsFor more information

Contact Us